peptides<\/a>.<\/p>\nHow Does TB-500 Work?<\/h2>\n
The mechanisms below are based on laboratory studies of Thymosin Beta-4 and its actin binding-region. They refer to processes observed in experimental models, not recognized effects in humans.<\/p>\n
Actin regulation<\/h3>\n
Actin is found in two forms: G actin is the free monomer and F actin is the filament that is formed when monomers assemble. It is the assembly and disassembly that make it possible for a cell to change shape, to extend out and to pull itself along. Thymosin Beta-4 binds G-actin and serves as a reservoir, affecting the availability of actin filaments. The fragment came under research focus due to its central role in the interaction, which includes the LKKTETQ actin-binding sequence.<\/p>\n
Cell migration<\/h3>\n
All movement is related to the dynamics of the cytoskeleton. Laboratory studies have looked at the effects on various cells that play a role in repair, such as fibroblasts (which form connective tissue), endothelial cells (which line blood vessels) and keratinocytes (which resurface skin). The overwhelming majority of the published evidence base is based on migration assays in cell culture.<\/p>\n
Angiogenesis<\/h3>\n
Blood supply is required for new tissue. The idea of Thymosin Beta-4 as a factor which affects the development of new vessels has been explored, such as studies of VEGF signalling and endothelial cell behaviour. While repair is a normal and necessary process of angiogenesis, it is also a process of great biological implication, which is described below.<\/p>\n
Inflammatory signalling<\/h3>\n
There is a close association between repair and inflammation. There has been a study of effects on the production of cytokines and inflammatory pathways in experimental models to better understand the interaction of the protein with immune signalling in the early stages of tissue injury. These are still lab-generated systems and not observed clinical results.<\/p>\n
Current Areas of Scientific Research<\/h2>\nTissue repair<\/h3>\n
Preclinical studies have focused on examining how skin, tendon, muscle, and ligament (and other pathways) respond to injury (usually in animal models or cultured cells). Biomarkers of cellular activity and structural recovery have been studied. Again, these are pre-clinical models, which are selected for their tractability and not for their predictive value in humans.<\/p>\n
Wound healing research<\/h3>\n
This is the most developed area. Studies have been conducted on epithelial healing, remodelling of the extracellular matrix, collagen structure and movement of fibroblasts. Full-length Thymosin Beta-4 has been studied in various dermal wound models, including chronic wound models in which normal wound healing mechanisms are impaired.<\/p>\n
Cardiac research<\/h3>\n
After myocardial injury, animal studies have investigated the processes of angiogenesis and cardiac remodelling following ischaemic injury. This sparked strong interest as heart tissue regrows poorly. The results are preliminary and are not intended to represent clinical efficacy.<\/p>\n
Eye research<\/h3>\n
Models of corneal wounds have been employed for the study of epithelial migration and the repair of the ocular surface. The cornea is a convenient research model, due to its accessibility, avascularity and ability to heal in a well described manner. Thymosin Beta-4 has been studied in early phase clinical trials as part of ocular surface disease.<\/p>\n
Inflammation research<\/h3>\n
Outside of wound studies, multiple studies have investigated immune signalling and inflammatory pathways individually, in order to gain insight into mechanism, not treatment.<\/p>\n
Regenerative medicine<\/h3>\n
The overall purpose is conceptual. Whether this molecule is ever to be a treatment or not, understanding the internal scaffolding structure of the cells and interaction with their movement during repair has relevance to tissue engineering, biomaterials and future approaches to regeneration.<\/p>\n
What Do Current Studies Show?<\/h2>\n
Observations of cell migration, tissue regeneration in animal models, angiogenesis, cytoskeletal regulation and inflammatory signalling have been published in the laboratory. Combined these characterise a molecule with potential experimental biological activity.<\/p>\n
However, experimental findings should not be interpreted as evidence of clinical effectiveness. Experimental results obtained from cell culture and animal models often don’t make it to humans; this can be due to various factors such as differences in physiology, dosing, delivery, and the complexity of the disease itself. These results do not necessarily represent proven benefits for humans.<\/p>\n
Human Research<\/h2>\n
However, there is little human evidence. Preliminary studies have been performed in certain settings, such as the eye surface and skin wounds, mostly with limited numbers of subjects and with the primary intent of safety and tolerability evaluation.<\/p>\n
There is no significant published programme of RCTs for the synthetic TB-500 fragment in particular. It is unknown whether that absence is due to questions of effectiveness, the context of use, or long-term safety and interactions with other conditions. Further, larger and well-designed clinical research is needed for conclusions to be reasonably drawn.<\/p>\n
Is TB-500 Approved in the UK?<\/h2>\n
TB-500 is not approved as a medicine by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). It does not have any evidence of efficacy for any condition and is not recommended by any NICE guideline.<\/p>\n
It is not regarded as a therapeutic agent but rather a laboratory research peptide in regulatory terms. Researchers collaborating with this type of compound will be expected to abide by the ethical approval procedures followed at their institution and all regulatory requirements pertaining to research materials.<\/p>\n
TB-500 and Sport<\/h2>\n
Thymosin beta-4 and its derivatives are on the WADA list of banned substances, and banned at all times (in-competition and out-of-competition). It belongs to the class of peptide hormones, growth factors and mimetics.<\/p>\n
It has serious ramifications for those who play in a WADA approved format. There is no evidence that an anti-doping violation brings any performance benefit and no protection if it is not approved by regulations. Competitive athletes should be aware that TB-500 and related compounds are prohibited under the WADA Prohibited List.<\/p>\n
Safety Considerations<\/h2>\n
Questions relating to safety are left open. The areas listed below are under ongoing assessment:<\/p>\n
\n- Long-term safety which is not adequately characterised by an existing dataset.<\/li>\n
- Pharmacology:<\/strong> behaviour of a fragment in living systems and clearance.<\/li>\n
- Toxicology<\/strong> over the range of exposures of relevance.<\/li>\n
- Immune response, such as reactions to a synthetic peptide.<\/li>\n
- Theoretical issues brought up by angiogenesis research – because new blood vessel formation has been discussed in the context of tumour biology<\/li>\n<\/ul>\n
That last is an area of scientific debate, not a fact of this compound, and is a testament to the slow nature of regenerative research. There is a lack of robust human safety data; conclusions about safety in either direction cannot be drawn at this time.<\/p>\n
Why Scientists Continue Studying TB-500<\/h2>\n
Research is ongoing due to the underlying biology being truly interesting. Cell motion is at the heart of tissue repair, and tissue repair is at the heart of cell motion, and with cell motion, actin dynamics. An investigation into the mechanism of action of a small molecule that interacts with that system can be achieved by studying that molecule.<\/p>\n
The broader fields with which it interacts (such as wound biology, tissue engineering, cellular repair mechanisms and translational regenerative medicine) are fields where much is still to be understood. It is important to understand how to make a compound into a medicine, but that is not the only reason to worth doing research.<\/p>\n
Conclusion<\/h2>\n
TB-500 is an experimental research peptide. Not a licensed medicine in the UK, nor an approved treatment and not recommended by NICE. There is a body of preclinical work – cell culture studies and animal models – documenting interesting biological activity in processes linking to tissue repair.<\/p>\n
The only real difference between TB-500 and Thymosin Beta-4 is what it does. Many of the arguments made in favour of the fragment were actually based on the full-length protein and the two are not interchangeable. Anyone reading about this peptide needs to understand which peptide was the molecule studied.<\/p>\n
There is a scientific interest that is likely to continue, as the questions raised are beyond this one compound: How do the cells move; how does the tissue rebuild; how can repair be supported? This interest does not necessarily mean there is evidence of benefit, and bigger, well-designed human studies would be required before anything useful could be said about effectiveness or safety in humans.<\/p>\n
If you are following this area, it is prudent to follow the primary literature through PubMed and NCBI and regulatory aspects through the MHRA, NICE and WADA.<\/p>\n","protected":false},"excerpt":{"rendered":"
TB-500 is mentioned more in online discussion than in clinical literature. It is a synthetic peptide (an area of study,…<\/p>\n","protected":false},"author":1,"featured_media":82,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[17],"class_list":["post-81","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptide-research","tag-tb-500-research"],"_links":{"self":[{"href":"https:\/\/www.doctorsnhs.co.uk\/knowledge-center\/wp-json\/wp\/v2\/posts\/81","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.doctorsnhs.co.uk\/knowledge-center\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.doctorsnhs.co.uk\/knowledge-center\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.doctorsnhs.co.uk\/knowledge-center\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.doctorsnhs.co.uk\/knowledge-center\/wp-json\/wp\/v2\/comments?post=81"}],"version-history":[{"count":2,"href":"https:\/\/www.doctorsnhs.co.uk\/knowledge-center\/wp-json\/wp\/v2\/posts\/81\/revisions"}],"predecessor-version":[{"id":84,"href":"https:\/\/www.doctorsnhs.co.uk\/knowledge-center\/wp-json\/wp\/v2\/posts\/81\/revisions\/84"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.doctorsnhs.co.uk\/knowledge-center\/wp-json\/wp\/v2\/media\/82"}],"wp:attachment":[{"href":"https:\/\/www.doctorsnhs.co.uk\/knowledge-center\/wp-json\/wp\/v2\/media?parent=81"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.doctorsnhs.co.uk\/knowledge-center\/wp-json\/wp\/v2\/categories?post=81"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.doctorsnhs.co.uk\/knowledge-center\/wp-json\/wp\/v2\/tags?post=81"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}